GILD

Gilead Sciences, Inc. - Q2 2004 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2004. Gilead Sciences, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for infectious diseases, primarily HIV and Hepatitis B. The company operates in a single business segment and relies heavily on collaborations with major pharmaceutical partners for marketing and distribution.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 34% in Q2 and 56% YTD compared to 2003. Product sales rose 30% in Q2, driven primarily by Viread (HIV treatment) and Hepsera (Hepatitis B treatment).
• Profitability: The company reported a net income of $111.5 million for Q2 2004, a significant turnaround from the net loss of $337.7 million in the same period in 2003. The 2003 loss included a $488.6 million charge for in-process research and development (IPR&D) related to the Triangle Pharmaceuticals acquisition.
• One-Time Gains: YTD 2004 results include a $20.6 million gain from the revaluation of EyeTech warrants and a $2.3 million gain from the sale of EyeTech stock.
• Expense Reclassification: Certain phase IV clinical trial expenses ($4.9 million in Q1 2004 and $4.5 million in Q2 2003) were reclassified from Selling, General, and Administrative (SG&A) to Research and Development (R&D) to better reflect their nature.

Guidance, Outlook, and Risks

• Revenue Guidance: Management expects full-year 2004 HIV franchise sales (Viread, Emtriva, Truvada) to range between $850 million and $875 million. AmBisome sales are expected to be lower in 2004 than 2003, projected between $170 million and $190 million due to increased competition in Europe.
• Expense Outlook: R&D expenses for 2004 are expected to be $200 million to $220 million (20-30% higher than 2003). SG&A expenses are projected at $300 million to $320 million (28-37% higher than 2003) due to marketing launches for Emtriva, Hepsera, and Truvada.
• Key Risks:
  • Product Dependence: Significant reliance on Viread and AmBisome for operating income.
  • Competition: New competitors in the Hepatitis B market (threatening Hepsera) and HIV market (threatening Truvada).
  • Regulatory & Safety: Potential for new safety issues or regulatory delays for new products like Truvada.
  • Foreign Currency: A significant portion of sales is denominated in foreign currencies; a stronger U.S. dollar could negatively impact results.
  • Wholesaler Inventory: Fluctuations in U.S. wholesaler inventory levels can cause unpredictable quarterly revenue swings.
• Subsequent Event: On July 28, 2004, the Board approved a two-for-one stock split. Share amounts in this report have not been adjusted to reflect the split.

Investor Verification Checklist

• Wholesaler Inventory Levels: Verify current inventory levels at major U.S. distributors (Amerisource, Cardinal, McKesson) to assess the sustainability of Viread sales growth.
• Truvada Launch Progress: Monitor regulatory approval status and market acceptance of the new fixed-dose combination (Truvada) in the U.S. and EU.
• European Reimbursement: Confirm reimbursement status and pricing for Hepsera and Truvada in key European markets (France, Spain, UK, Italy).
• EyeTech Transaction: Note that the $20.6 million warrant gain and $2.3 million stock sale gain are non-recurring items and should be excluded when analyzing core operating performance.
• AmBisome Competition: Assess the impact of new generic or competing antifungal products on AmBisome sales volume in Europe.